



pan-Canadian Oncology Drug Review Final Clinical Guidance Report

Bendamustine (Treanda) for First Line CLL

February 19, 2013

DISCLAIMER

Not a Substitute for Professional Advice

This report is primarily intended to help Canadian health systems leaders and policymakers make well-informed decisions and thereby improve the quality of health care services. While patients and others may use this report, they are made available for informational and educational purposes only. This report should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision making process, or as a substitute for professional medical advice.

Liability

pCODR does not assume any legal liability or responsibility for the accuracy, completeness or usefulness of any information, drugs, therapies, treatments, products, processes, or services disclosed. The information is provided "as is" and you are urged to verify it for yourself and consult with medical experts before you rely on it. You shall not hold pCODR responsible for how you use any information provided in this report.

Reports generated by pCODR are composed of interpretation, analysis, and opinion on the basis of information provided by pharmaceutical manufacturers, tumour groups, and other sources. pCODR is not responsible for the use of such interpretation, analysis, and opinion. Pursuant to the foundational documents of pCODR, any findings provided by pCODR are not binding on any organizations, including funding bodies. pCODR hereby disclaims any and all liability for the use of any reports generated by pCODR (for greater certainty, "use" includes but is not limited to a decision by a funding body or other organization to follow or ignore any interpretation, analysis, or opinion provided in a pCODR report).

FUNDING

The pan-Canadian Oncology Drug Review is funded collectively by the provinces and territories, with the exception of Quebec, which does not participate in pCODR at this time.

INQUIRIES

Inquiries and correspondence about the pan-Canadian Oncology Drug Review (pCODR) should be directed to:

pan-Canadian Oncology Drug Review
1 University Avenue, suite 300
Toronto, ON
M5J 2P1

Telephone: 416-673-8381
Fax: 416-915-9224
Email: info@pcodr.ca
Website: www.pcodr.ca

TABLE OF CONTENTS

DISCLAIMER AND FUNDING	ii
INQUIRIES	iii
TABLE OF CONTENTS	iv
1 GUIDANCE IN BRIEF	1
1.1 Background	1
1.2 Key Results and Interpretation	1
1.2.1 A) Previously Untreated (First Line) Chronic Lymphocytic Leukemia	1
1.2.2 Additional Evidence	2
1.2.3 Interpretation and Guidance	2
1.3 Conclusions	3
2 CLINICAL GUIDANCE	3
2.1 Context for the Clinical Guidance	3
2.1.1 Introduction	3
2.1.2 Objectives and Scope of pCODR Review	4
2.1.3 Highlights of Evidence in the Systematic Review	4
2.1.3 A) Previously Untreated (First Line) Chronic Lymphocytic Leukemia	4
2.1.4 Comparison with Other Literature	8
2.1.5 Summary of Supplemental Questions	8
2.1.6 Other Considerations	8
2.2 Interpretation and Guidance	9
2.3 Conclusions	11
3 BACKGROUND CLINICAL INFORMATION	12
4 SUMMARY OF PATIENT ADVOCACY GROUP INPUT	15
5 SUMMARY OF PROVINCIAL ADVISORY GROUP (PAG) INPUT	21
6 SYSTEMATIC REVIEW	24
6.1 Objectives	24
6.2 Methods	24
6.3 Results	27
6.3 A) Results for Previously Untreated (First-Line) Indolent Lymphoma	27
6.4 Ongoing Trials	37
7 SUPPLEMENTAL QUESTIONS	38
8 ABOUT THIS DOCUMENT	39
APPENDIX A: LITERATURE SEARCH STRATEGY	40
REFERENCES	42

1 GUIDANCE IN BRIEF

1.1 Background

The objective of this review is to evaluate the effect of bendamustine, either as a single agent or in combination with other chemotherapeutic agents on patient outcomes compared to appropriate comparators in the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).

1.2 Key Results and Interpretation

Systematic Review Evidence

1.2.1 Previously Untreated (First Line) Chronic Lymphocytic Leukemia

One open-label multicentre randomized control trial, Study 02CLLIII, was identified that met the inclusion criteria for this review.¹⁻⁹ The trial was designed to evaluate superiority of bendamustine compared to chlorambucil for two primary outcomes: progression-free survival and overall response rate in previously untreated CLL. A total of 319 patients (Age ≤ 75 years, WHO PS/ECOG 0-2) were randomized in a 1:1 ratio to receive bendamustine monotherapy 100 mg daily on day 1 and 2 given i.v. over 30 minutes, every 4 weeks (n=162) or to chlorambucil CLB 0.8 mg/kg (Broca's normal weight in kg) on days 1 and 15 orally, every 4 weeks (n=157).

Study 02CLLIII had two primary endpoints, progression-free survival and overall response rate.¹ Progression-free survival based on the independent review committee assessments demonstrated a statistically significant difference for bendamustine (median 21.6 months) compared to chlorambucil (median 8.3 months), with HR=0.214, $p < 0.0001$.¹ A statistically significant difference in overall response rates was demonstrated for bendamustine (68% of 162 patients) compared to chlorambucil (31% of 157 patients; $p < 0.0001$), based on the independent review committee assessments.¹ No data was reported to support quality of life statements.

A higher proportion of patients in the bendamustine arm than in the chlorambucil arm experienced neutropenia (any grade or Grade 3/4), leukopenia (any grade or Grade 3/4), vomiting (any grade), pyrexia (any grade), infection (any grade) or rash (any grade).¹ None of the study reports indicated whether any of these differences were statistically different. A total of 72 patients (31 in the bendamustine arm and 41 in the chlorambucil arm) have died during the follow-up period.

1.2.2 Additional Evidence

pCODR received input on bendamustine from the following patient advocacy groups: The Leukemia and Lymphoma Society of Canada and The CLL Patient Advocacy Group. Provincial Advisory group input was obtained from the nine provinces (Ministries of Health and/or cancer agencies) participating in pCODR.

1.2.3 Interpretation and Guidance

Chronic lymphocytic leukemia (CLL) represents the most common leukemia in the western world, and affects 4.2 people/100 000 population per year. Cure of this disease is not a reasonable expectation and most affected patients will eventually die as a result of their disease with the median survival from the time patients require treatment for CLL being approximately 4 years.

The majority of patients with CLL are older and so are not considered suitable candidates for modalities such as intensive chemotherapy regimens and stem cell transplantation. Having fewer options, older patients usually receive treatment with single agents, occasionally in combination with rituximab. The two classes of drugs most often used to treat CLL are nucleoside analogues and alkylating agents. As none of these treatments is expected to be curative and all are expected to be associated with significant side effects, there is a need for new drugs to treat CLL.

Bendamustine is a novel bifunctional alkylating agent with a similar mechanism of action and side effect profile as chlorambucil making it an appropriate comparator in front-line therapy. As many older patients are treated with alkylating agents initially, fludarabine is an appropriate comparator for patients being treated for relapsed disease.

Study 02CLLIII comparing bendamustine and chlorambucil in untreated patients with CLL demonstrated a clinically-significant improvement in progression-free survival among patients treated with bendamustine. The overall and complete response rates were significantly higher with bendamustine than they were with chlorambucil. Although statistically not significant, rates of grade 3 / 4 cytopenias were higher among patients treated with bendamustine compared with chlorambucil.

1.3 Conclusions

The Clinical Guidance Panel concluded that there is an overall clinical benefit to bendamustine in the treatment of previously-untreated patients with CLL who are not suitable candidates for more intensive regimens. This conclusion is based on the results of one high-quality randomized, active control study comparing bendamustine with chlorambucil (Study 02CLLIII) that demonstrated a clear clinically- and statistically-significant improvement in progression-free survival. In reaching this conclusion, the Clinical Guidance Panel considered that:

- Study 02CLLIII showed a clear benefit to untreated patients with Binet stage B or C CLL who were under the age of 75 and had ECOG performance status 0 - 2.
- While patients with CLL may initially be observed, most eventually require treatment for their disease. Treatment options for older or unfit patients are limited.
- The frequency and severity of adverse events observed with bendamustine are consistent with the adverse events seen with other front-line regimens for CLL. Physicians who treat CLL are comfortable managing patients with grade 3 / 4 cytopenias. Extramedullary toxicity was generally mild.

2 CLINICAL GUIDANCE

This Clinical Guidance Report was prepared to assist the pCODR Expert Review Committee (pERC) in making recommendations to guide funding decisions made by the provincial and territorial Ministries of Health and provincial cancer agencies regarding Bendamustine (Treanda) for CLL. The Clinical Guidance Report is one source of information that is considered in the *pERC Deliberative Framework*. The *pERC Deliberative Framework* is available on the pCODR website, www.pcodr.ca.

This Clinical Guidance is based on: a systematic review of the literature regarding Bendamustine (Treanda) for CLL conducted by the Leukemia Clinical Guidance Panel (CGP) and the pCODR Methods Team; input from patient advocacy groups; input from the Provincial Advisory Group; and supplemental issues relevant to the implementation of a funding decision.

The systematic review and supplemental issues are fully reported in Sections 6 and 7. Background Clinical Information provided by the CGP, a summary of submitted Patient Advocacy Group Input on Bendamustine (Treanda) for CLL and a summary of submitted Provincial Advisory Group Input on Bendamustine (Treanda) for CLL are provided in Sections 3, 4 and 5 respectively.

2.1 Context for the Clinical Guidance

2.1.1 Introduction

With an age-adjusted incidence rate of 4.2 cases/100 000 population, CLL represents the most common leukemia in western countries. CLL is a disease of the elderly, with a median age at diagnosis of 72 years, and its long natural history (median survival from diagnosis is 10+ years) reflects an extended period of watchful waiting in most patients.¹⁰ Treatment is normally reserved for patients with symptomatic disease, as cure is not a realistic goal with current modalities.

Common indications to treat patients with CLL include the development of cytopenias (Rai stage 3 or 4 disease), bulky lymphadenopathy or splenomegaly, B-symptoms or rapid lymphocyte doubling (< 3 months). Treatment is individualized based on patients' suitability for intensive chemotherapy. The combination of fludarabine, cyclophosphamide and rituximab (FCR) has become the standard of care for young, otherwise healthy patients given the results of a recent German CLL Study Group study showing improved PFS (51.8 vs. 32.8 months, $p < 0.0001$) and OS (87% vs. 83%, $p = 0.012$) with the addition of rituximab to FC.¹¹ Significant and prolonged neutropenia and leucocytopenia and frequent extramedullary toxicity make this regimen unsuitable for older and less fit individuals.

Patients who are not considered fit enough to receive FCR but who are still suitable to receive treatment may derive benefit from several less intensive regimens. Chlorambucil, an alkylating agent, has been in use for more than 30 years and can be given in daily, weekly, biweekly and monthly schedules. Extramedullary toxicity is generally mild and transient. Other alkylator-based regimens, such as cyclophosphamide and prednisone or CVP have been described in CLL (see Table 2). The nucleoside analog fludarabine was compared with chlorambucil in a seminal phase 3 study showing improved complete response rates and PFS but similar OS.¹² Patients treated with fludarabine in this study had higher rates of severe infection and neutropenia, and the combination of fludarabine and chlorambucil has been associated with unacceptably high rates on severe infection.¹³ The addition of monoclonal antibodies to induction regimens for less fit patients is an area of active research, but appears promising in early-phase studies. Novel agents such as lenalidomide¹⁴ and new

monoclonal antibodies such as ofatumumab¹⁵ have been evaluated in CLL but have yet to find their place in the therapeutic arsenal for this disease.

While survival from diagnosis in CLL may exceed 10 years, survival from the onset of treatment is only 4 years and contrary to widely held belief, 70% of patients with CLL die of causes related to their disease. New, more effective treatments for patients with this disease are desperately needed.

Bendamustine hydrochloride was developed in East Germany in the 1960's.¹⁶ It is a purine analogue/alkylator hybrid that has shown activity in various cancers.¹⁷ It is composed of a 2-chloroethylamine group, a benzimidazole ring, and a butyric acid side chain and has been shown to have a unique mechanism of action in comparison to other alkylating agents such as cyclophosphamide or chlorambucil.¹⁷ Bendamustine is approved by Health Canada for the following indications: 1) indolent non-Hodgkin lymphoma that has progressed during or shortly following treatment with a rituximab regimen; and, 2) previously untreated CLL.^{18,19}

2.1.2 Objectives and Scope of pCODR Review

To evaluate the effect of bendamustine, either as a single agent or in combination with other chemotherapeutic agents on patient outcomes compared to appropriate comparators in the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).

See Table 8 in Section 6.2.1 for outcomes of interest and appropriate comparators.

See Section 6.2.1 for more details on the pCODR systematic review protocol.

2.1.3 Highlights of Evidence in the Systematic Review

This section describes highlights of evidence in the systematic review. Refer to section 2.2 for the clinical interpretation of this evidence and section 6 for more details of the systematic review.

2.1.3 A) Previously Untreated (First-Line) Chronic Lymphocytic Leukemia

Trial Characteristics

One open-label multicentre RCT (O2CLLIII) was identified that met the inclusion criteria for this review.¹⁻⁹ The study investigated the use of bendamustine compared to chlorambucil in patients less than 75 years old with previously untreated Binet stage B or C CLL. A summary of key trial characteristics can be found in Table 1.

The trial was designed to evaluate superiority of bendamustine compared to chlorambucil for two primary outcomes: progression-free survival and overall response rate.¹⁻⁹ The trial used a group sequential design with planned interim analyses. The investigators estimated that approximately 350 patients would be required if a fixed sample design was used. After the third interim analysis including 305 patients, the Independent Data Monitoring Committee recommended that patient recruitment be stopped after 319 patients were enrolled. The analyses of the primary outcomes were to be stratified by Binet stage.

A total of 319 patients were randomized in a 1:1 ratio to receive bendamustine monotherapy (100 mg/m²/d on days 1 and 2 of a 4-week cycle; n=162) or to chlorambucil (0.8 mg/kg, Broca's normal weight in kg; n=157). Patients received up to a maximum of

six cycles of therapy. A median of six treatment cycles were administered in both treatment arms. The mean number of cycles was 4.9 (standard deviation, 1.7).

The two arms were balanced for a number of baseline demographic and disease characteristics, including; World Health Organization (WHO) performance status, B symptoms, lactate dehydrogenase, and time from initial diagnosis to enrolment. A similar number of female patients were enrolled in each arm (37.0% in the bendamustine arm and 39.5% in the chlorambucil arm). Of 162 patients in the bendamustine arm 71.6% had Binet stage B disease and 28.4% had Binet stage C. Similarly, of 157 patients in the chlorambucil arm, 70.7% had Binet stage B disease and 29.3% had Binet stage C. The mean ages of patients in each arm were similar (bendamustine arm, 63.0 years; chlorambucil arm 63.6 years) as was the median age (bendamustine, 63.0 years; chlorambucil arm 66.0 years).

Of 319 randomized patients, 18 patients had protocol violations: 11 did not meet the diagnostic confirmation required in the protocol, and seven did not receive the allocated intervention (one in the bendamustine arm and six in the chlorambucil arm). No patients were lost to follow-up in the bendamustine arm and only one patient was lost to follow-up in the chlorambucil arm.

Neither the investigators nor the patients were blinded to treatment assignment; however, the trial protocol was amended to include independent and blinded tumour assessments, thus reducing the risk of bias in the assessments of response and progression-free survival. The 18 patients with protocol violations also represented, at most, 5.6% of the study population and therefore likely had little impact on the study results.

Table 1. Summary of Included Studies in Study 02CLLIII.¹

Trial Design	Inclusion Criteria	Interventions and Comparators	Outcomes
<p>Study 02CLLIII</p> <p>Multicenter study: 45 sites in 8 countries in Europe*</p> <p>Study start date: November 2002; Study completion: November 2006</p> <p>Open-label, active control RCT</p> <p>Randomized in a 1:1 ratio (BEN:CLB) stratified by center and Binet stage</p> <p>Randomized: n=319 Analysis ITT: n=319</p> <p>Funded by: Ribosepharm GmbH, Germany and Mundipharma</p>	<p>Patients with previously untreated CLL with Binet stage B (≥3 lymph node regions involved including hepatomegaly and splenomegaly) or Binet stage C (anemia and/or thrombocytopenia regardless of the number of lymph node regions) with coexpression of CD5, CD23 and either CD19, or CD20, or both.</p> <p>Age ≤75 years</p> <p>WHO PS 0-2</p> <p>Life expectancy >3 months</p>	<p>Two arms:</p> <p>BEN 100 mg/m²/d d1,2 i.v. over 30 minutes, every 4 weeks</p> <p><i>Or:</i></p> <p>CLB 0.8 mg/kg (Broca's normal weight in kg) on days 1 and 15 orally, every 4 weeks.</p> <p>Prophylactic use of hyperuricemia treatment was recommended to prevent uric acid-induced nephropathy.</p>	<p><u>Co-Primary</u></p> <p>Overall response rate</p> <p>Progression-free survival</p> <p><u>Secondary</u></p> <p>Time-to-progression</p> <p>Duration of remission</p> <p>Overall survival</p> <p>Adverse events</p> <p>Infection</p>

Trial Design	Inclusion Criteria	Interventions and Comparators	Outcomes
International, U.K.			

Notes: BEN=bendamustine; CLB=chlorambucil; ITT=intention-to-treat; i.v.=intravenous; RCT=randomized controlled trial; WHO PS=World Health Organization performance status.

*Countries included Austria, Bulgaria, France, Germany, Italy, Spain, Sweden, and the United Kingdom.

Outcome Data and Summary of Outcomes

The final efficacy intent-to-treat analysis included all 319 randomized patients (bendamustine arm, n=162; chlorambucil arm, n=157).¹ The safety analysis included all 312 treated patients (161 patients in the bendamustine arm and 151 patients in the chlorambucil arm).¹ A summary of key efficacy and harms outcomes can be found in Table 2 below.

Table 2. Summary of Key Trial Outcomes From Study 02CLLIII.¹

Efficacy	Analysis	Intervention	Median [months]	HR (95% CI)	p-value	Median follow-up [months]
Progression-free Survival	Analysis using Independent Review Committee Assessments ^A	Bendamustine (n=162) Chlorambucil (n=157)	21.6 8.3	0.214 (NR)	p<0.0001	35
	Sensitivity analysis using strictly applied NCI-WG criteria ^B	Bendamustine (n=162) Chlorambucil (n=157)	17.6 5.7	0.269 (0.169-0.428)	p<0.0001	35
Efficacy		Intervention	Rate (%)		p-value	
Response	CR	Bendamustine (n=162) Chlorambucil (n=157)	31 2		p=NR	
	OR	Bendamustine (n=162) Chlorambucil (n=157)	68 31		p<0.0001	

Harms	Bendamustine (n=161)	Chlorambucil (n=151)
Withdrew due to AE (%)	11.2	3.3
At least one AE (%)	89	81
At least one Grade 3 or 4 AE (%)	55 ^C	32 ^C
Neutropenia		
Any Grade (%)	27.3	13.9
Grade 3/4 (%)	23.0	10.6
Thrombocytopenia		
Any Grade (%)	24.8	20.5
Grade 3/4 (%)	11.8	7.9
Anemia		
Any Grade (%)	21.7	13.9
Grade 3/4 (%)	2.5	0
Leukopenia		
Any Grade (%)	17.4	3.3
Grade 3/4 (%)	14.3	1.3
Nausea (any Grade, %)	19.3	13.9
Vomiting (any Grade, %)	15.5	6.6
Pyrexia (any Grade, %)	24.8	5.3
Infection (any Grade, %)	6.2	1.3
Rash (any Grade, %)	9.3	4.6

Notes: AE=adverse event; CI=confidence interval; CR=complete response; HR=hazard ratio; NCI-WG=National Cancer Institute-Working Group; NR=not reported; OR=overall response; SAE=serious adverse event.

^AData obtained from primary publication.¹

^BData obtained from FDA Medical Review.²⁰

^CData obtained from Product Monograph.¹⁹

Progression-free survival based on the independent review committee assessments demonstrated a statistically significant difference for bendamustine (median 21.6 months) compared to chlorambucil (median 8.3 months), with HR=0.214, p<0.0001.¹ The FDA Medical review reported a sensitivity analysis of progression-free survival where a computer algorithm was used to strictly apply the NCI-WG criteria. That analysis also demonstrated a statistically significant difference in progression-free survival for bendamustine (median 17.6 months) compared to chlorambucil (median 5.7 months), with HR=0.269, 95% confidence interval (CI) 0.169-0.428, p<0.0001.²⁰ Median follow-up was 35 months.

A total of 72 patients (31 in the bendamustine arm and 41 in the chlorambucil arm) died during the follow-up period. At the time of the final analysis, there were insufficient data to comment on overall survival.¹ In 2012, Knauf et al reported updated results for the 02CLLIII study.² The analysis was conducted in May 2010 on the final intent-to-treat population (N=319). After a median follow-up of 54 months, with a total of 132 deaths, no statistically significant difference in overall survival was observed for the bendamustine arm (median not yet reached) compared to the chlorambucil arm (median 78.8 months; HR 0.77 95% CI 0.52-1.12).²

A statistically significant difference in overall response rate was demonstrated for bendamustine (68% of 162 patients) compared to chlorambucil (31% of 157 patients; p<0.0001), based on the independent review committee assessments.¹

Although some qualitative statements regarding the quality of life study accompanying the 02CLLIII study were reported at ASH in 2010 and in the Health Canada review, no data were reported to support the statements.^{3,18}

Rates of harms outcomes can be found in Table 2; however, none of the study reports indicated whether any of the differences were statistically different. Of note, more patients in the bendamustine arm than in the chlorambucil arm withdrew due to an adverse event.¹ In addition, 55% of patients in the bendamustine arm experienced a Grade 3 or 4 adverse event compared to 32% of patients in the chlorambucil arm.¹⁹ A higher proportion of patients in the bendamustine arm than in the chlorambucil arm experienced neutropenia (any grade or Grade 3/4), leukopenia (any grade or Grade 3/4), vomiting (any grade), pyrexia (any grade), infection (any grade) or rash (any grade).¹ Tumour lysis syndrome occurred in two patients in the bendamustine arm after the first cycle—neither was fatal and both patients continued treatment.¹

2.1.4 Comparison with Other Literature

The pCODR Clinical Guidance Panel and the pCODR Methods Team did not identify other relevant literature providing supporting information for this review.

2.1.5 Summary of Supplemental Questions

No supplemental issues were identified during the development of this report.

2.1.6 Other Considerations

Patient Advocacy Group Input

PAG Input

Other

The product monograph for Treanda (bendamustine hydrochloride) provided by the manufacturer (Lundbeck Canada Inc.) provides the following serious warnings and precautions:¹⁹

- ***Clinically Significant Adverse Events:***

- *Myelosuppression*

- Patients treated with Treanda are likely to experience myelosuppression. In the NHL study, 98% of patients had Grade 3-4 myelosuppression. Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection. Hematologic nadirs were observed predominantly in the third week of therapy. In the clinical trials, blood counts were monitored every week initially.

- In the event of treatment-related myelosuppression, monitor leukocytes, platelets, hemoglobin (Hgb) and neutrophils closely. Hematologic nadirs may require dose delays if recovery to the recommended values have not occurred by the first day of the next scheduled cycle. Prior to the initiation of the next cycle of therapy, the absolute neutrophil count [ANC] should be $\geq 1 \times 10^9/L$ and the platelet count should be $\geq 75 \times 10^9/L$.

Infections, Including Fatalities

Cytomegalovirus (CMV) infections were reported in 3% of patients in the NHL study and were responsible for at least one death. CMV testing should be considered in patients with fever of unknown origin. The use of live attenuated vaccines should be avoided.

Herpes zoster was reported in 12% of patients in the NHL study (Grade 3: 4%; Grade 4; 0%).

Patients should be informed about early signs and symptoms of herpes zoster and should seek treatment as early as possible.

Second Malignancies

Pre-malignant and malignant diseases have developed in patients treated with Treanda including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia and bronchial carcinoma. Bendamustine is mutagenic, genotoxic and carcinogenic with cancers reported following subcutaneous and oral delivery of the drug to mice.

- ***Treanda should not be used in patients with serious infections:***

Treanda should not be administered to patients with serious infections, including patients with HIV. Infections, including pneumonia and sepsis, have been reported in patients in clinical trials and in post-marketing reports. Infections have been associated with hospitalization, septic shock and death. Patients with myelosuppression following treatment with Treanda are more susceptible to infections and should be advised to contact a physician if they have symptoms or signs of infection.

- ***Treanda should be administered under the supervision of a qualified health professional who is experienced in oncology.***

2.2 Interpretation and Guidance

Burden of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) represents the most common leukemia in the western world, and affects 4.2 people/100 000 population per year. Although the disease has an indolent course and most patients can be safely observed without treatment for many years, cure of this disease is not a reasonable expectation and most affected patients will eventually die as a result of their disease. Young patients may benefit from intensive chemotherapy regimens and possibly from stem cell transplantation, but the majority of patients with CLL are older and so are not considered suitable candidates for these modalities. Older patients have few options and usually receive treatment with single agents, occasionally in combination with rituximab. Most patients will receive multiple lines of chemotherapy and will experience shorter remissions after each cycle as the disease becomes more resistant to treatment. The median survival from the time patients require treatment for CLL is approximately 4 years.

Treatment of Chronic Lymphocytic Leukemia

In broad terms, the two classes of drugs most often used to treat CLL are nucleoside analogues and alkylating agents. These agents were developed in the middle decades of the twentieth century, and have well known safety profiles. The pivotal trial that compared fludarabine and chlorambucil in untreated patients with CLL demonstrated a 6-month improvement in median PFS (20 vs. 14 months, $p < 0.001$) with similar overall survival with both agents. Subsequent comparisons in elderly patients failed to demonstrate clinical benefit with fludarabine over chlorambucil, potentially due to increased toxicity in this population. While targeted therapy with small molecule inhibitors has not entered clinical practice, inhibitors of Bruton's tyrosine kinase (PCI-32765) and immunomodulatory drugs such as lenalidomide are in clinical trials currently. The monoclonal anti-CD20 antibody rituximab has been shown to improve overall and progression-free survival when added to regimens commonly used to treat CLL and later generation anti-CD20 antibodies such as ofatumumab and GA-101 have the potential to change treatment for this disease. As none of these treatments is expected to be curative and all are expected to be associated with significant side effects, there is a need for new drugs to treat CLL in the first line setting.

Bendamustine is a novel bifunctional alkylating agent originally developed in East Germany. Given its similar mechanism of action and side effect profile, chlorambucil is an appropriate comparator in front-line therapy. As many older patients are treated with alkylating agents initially, fludarabine is an appropriate comparator for patients being treated for relapsed disease.

Previously Untreated Patients with CLL

Study 02CLLIII

The systematic review identified a single well-conducted open-label randomized, active control trial comparing bendamustine and chlorambucil in untreated patients with CLL. As the routes of administration differ for these two agents allocation concealment was not possible. Response assessments were made by a central adjudication committee blinded to treatment allocation as a way of avoiding bias. In this study, a total of 319 patients were randomly assigned to receive bendamustine (100 mg/m²/day on days 1 and 2 of a 4-week cycle, $n=162$) or chlorambucil (0.8 mg/kg, Broca's normal weight in kg, $n=157$) in a 1:1 ratio for a maximum of six cycles of treatment. Eligible patients were younger than 75 years, had Binet stage B or C CLL and had never received treatment for their disease. Groups were balanced for demographic and disease characteristics. The primary outcomes of interest were overall response rate and progression-free survival. As CLL is a sequential-treatment disease overall survival was examined as a secondary outcome, as were time-to-progression, duration of remission, and rates of adverse events.

This study demonstrated a clinically-significant improvement in progression-free survival among patients treated with bendamustine. This group of patients experienced PFS of 21.6 months, compared with 8.3 months in patients treated with chlorambucil ($p < 0.0001$). The overall and complete response rates were significantly higher with bendamustine than they were with chlorambucil (OR 68% vs. 31%, $p < 0.0001$; CR 31% vs. 2%, $p = \text{NR}$). Rates of grade 3 / 4 cytopenias were higher among patients treated with bendamustine compared with chlorambucil but withdrawals due to adverse events were infrequent in either arm (11.2% with bendamustine vs. 3.3 with chlorambucil).

Summary

CLL is a common disease with a long natural history, and patients with this condition receive treatment on an intermittent basis as dictated by the activity and symptoms of their illness. Patient groups indicate that there is a need for more treatment options throughout the course of their disease. While the standard of care for young, fit patients is gradually shifting to moderately intensive combination regimens (i.e. fludarabine-cyclophosphamide-rituximab, FCR) there is no standard of care for older or less fit patients. The results of the systematic review suggest that bendamustine should have a place in the front-line management of patients not considered eligible for FCR.

The review raises several questions for future study:

- The Cumulative Illness Rating Scale (CIRS) score has been used to define eligibility for FCR chemotherapy. It is unclear whether this same scale can be used to define eligibility for bendamustine.
- The impact of biological risk factors such as deletions of 17p or 11q, IgH mutational status and ZAP-70 expression on outcome with bendamustine should be examined in future studies.

2.3 Conclusions

The Clinical Guidance Panel concluded that there is an overall clinical benefit to bendamustine in the treatment of previously-untreated patients with CLL who are not suitable candidates for more intensive regimens. This conclusion is based on the results of one high-quality randomized, active control study comparing bendamustine with chlorambucil (Study 02CLLIII) that demonstrated a clear clinically- and statistically-significant improvement in progression-free survival. In reaching this conclusion, the Clinical Guidance Panel considered that:

- Study 02CLLIII showed a clear benefit to untreated patients with Binet stage B or C CLL who were under the age of 75 and had ECOG performance status 0 - 2.
- While patients with CLL may initially be observed, most eventually require treatment for their disease. Treatment options for older or unfit patients are limited.
- The frequency and severity of adverse events observed with bendamustine are consistent with the adverse events seen with other front-line regimens for CLL. Physicians who treat CLL are comfortable managing patients with grade 3 / 4 cytopenias. Extramedullary toxicity was generally mild.

3 BACKGROUND CLINICAL INFORMATION

This section was prepared by the pCODR Leukemia Clinical Guidance Panel. It is not based on a systematic review of the relevant literature.

3.1 Description of the Condition

With an age-adjusted incidence rate of 4.2 cases/100 000 population, CLL represents the most common leukemia in western countries. CLL is a disease of the elderly, with a median age at diagnosis of 72 years, and its long natural history (median survival from diagnosis is 10+ years) reflects an extended period of watchful waiting in most patients.¹⁰ Treatment is normally reserved for patients with symptomatic disease, as cure is not a realistic goal with current modalities.

A diagnosis of CLL is normally suspected when an unexplained lymphocytosis is noted on blood counts, often done for another reason. Examination of a peripheral blood film demonstrates lymphocytes that are slightly larger than normal lymphocytes, with clumped chromatin and a thin crescent of pale cytoplasm. Prolymphocytes are infrequent, and the presence of > 55% prolymphocytes suggests a diagnosis of B-cell prolymphocytic leukemia.²¹ Further testing demonstrates the characteristic immunophenotype of CLL cells, which are typically kappa- or lambda-restricted CD19+, CD5+, CD23+, CD10-, CD11cdim, CD20dim, sIg dim B-cells with absent or dim expression of FMC-7 and CD79a. The 2008 WHO Classification indicates that in the absence of extramedullary involvement there must be $\geq 5 \times 10^9$ cells/L with this phenotype for a diagnosis of CLL to be made.²² Lymph node infiltration by B-lymphocytes with a CLL phenotype may occur in the absence of peripheral lymphocytosis: when this occurs a diagnosis of small lymphocytic lymphoma (SLL) is made. CLL and SLL are generally considered to be indolent lymphomas based on the mature appearance of the malignant cells and their similarity to other mature B-cell neoplasms. It is important to distinguish CLL from other peripheralizing lymphomas, such as mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma as treatment of these entities differs from that of CLL.

3.2 Accepted Clinical Practice

Two staging systems have been in use for CLL, with a strong preference for the Rai staging system in North America and for the Binet system in Europe (see Table 1).^{23,24} Both staging systems reflect the gradual infiltration of CLL target organs, lymph nodes, spleen and bone marrow by disease cells, with higher stages indicating impairment of bone marrow function. Advanced CLL with bone marrow impairment (Rai stage 3 or 4, Binet stage C) has poor prognosis and is a commonly accepted indication for treatment.

A large numbers of factors have been associated with adverse prognosis in CLL. Rapid cell turnover, reflected by a short lymphocyte doubling time, is associated with an aggressive clinical course and shortened survival. Plasma factors indicating rapid turnover including LDH, β_2 -microglobulin and thymidine kinase have also been confirmed to reflect adverse prognosis.²⁵

Early work examining the status of the immunoglobulin domain of CLL B-cells indicated that CLL may arise from either antigen naïve (without immunoglobulin gene somatic hypermutation) or antigen exposed (with somatic hypermutation) B-cells.^{26,27} These two disease subtypes have dramatically divergent clinical courses, with patients with unmutated disease having median survival of 8-9 years, compared with > 20 years for patients with

mutated immunoglobulin domains. The cumbersome nature of the technology necessary to determine the mutation status of IgH domains has limited the clinical utility of this assay and has instead led to the investigation of surrogate markers associated with these changes. Two such markers, CD38 and ZAP-70, have shown an imperfect correlation with mutational status, but nonetheless remain important and relevant prognostic factors in their own rights.²⁸⁻³⁰

Metaphase cytogenetics in CLL is hampered by the low mitotic rate of these cells in tissue culture. Interphase FISH has become a powerful tool in such situations, and allows the detection of clonal cytogenetic abnormalities on fixed tissue without the need to prepare metaphase spreads. Isolated 13q deletions are associated with favourable prognosis while deletions of 11q or 17p are associated with unmutated IgH and poor prognosis. Some studies have suggested that with appropriate treatment the prognosis of del (11q) cases can approach that of more favourable subgroups.³¹

Common indications to treat patients with CLL include the development of cytopenias (Rai stage 3 or 4 disease), bulky lymphadenopathy or splenomegaly, B-symptoms or rapid lymphocyte doubling (< 3 months). Treatment is individualized based on patients' suitability for intensive chemotherapy. The combination of fludarabine, cyclophosphamide and rituximab (FCR) has become the standard of care for young, otherwise healthy patients given the results of a recent German CLL Study Group study showing improved PFS (51.8 vs. 32.8 months, $p < 0.0001$) and OS (87% vs. 83%, $p = 0.012$) with the addition of rituximab to FC.¹¹ Significant and prolonged neutropenia and leucocytopenia and frequent extramedullary toxicity make this regimen unsuitable for older and less fit individuals.

Patients who are not considered fit enough to receive FCR but who are still suitable to receive treatment may derive benefit from several less intensive regimens. Chlorambucil, an alkylating agent, has been in use for more than 30 years and can be given in daily, weekly, biweekly and monthly schedules. Extramedullary toxicity is generally mild and transient. Other alkylator-based regimens, such as cyclophosphamide and prednisone or CVP have been described in CLL (see Table 7). The nucleoside analog fludarabine was compared with chlorambucil in a seminal phase 3 study showing improved complete response rates and PFS but similar OS.¹² Patients treated with fludarabine in this study had higher rates of severe infection and neutropenia, and the combination of fludarabine and chlorambucil has been associated with unacceptably high rates on severe infection.¹³ The addition of monoclonal antibodies to induction regimens for less fit patients is an area of active research, but appears promising in early-phase studies. Novel agents such as lenalidomide¹⁴ and new monoclonal antibodies such as ofatumumab¹⁵ have been evaluated in CLL but have yet to find their place in the therapeutic arsenal for this disease.

Table 6. Accepted staging systems for patients with chronic lymphocytic leukemia.

Staging System	Stage	Definition	Median OS (mo)
Rai	0	Blood/marrow lymphocytosis	126
	1	Lymphadenopathy	92
	2	Splenomegaly	53
	3	Anemia (Hb < 110)	23

Staging System	Stage	Definition	Median OS (mo)
	4	Thrombocytopenia (Plt < 100)	20
Binet	A	< 3 lymph node areas*	128
	B	≥ 3 lymph node areas	47
	C	Anemia (Hb < 100) or thrombocytopenia (Plt < 100)	24

* Lymph node areas for Binet staging are unilateral or bilateral cervical, axillary or inguinal lymph nodes, liver and spleen.

Table 7. Results of selected chemotherapy trials in chronic lymphocytic leukemia.³²⁻³⁵

Regimen	Entry Criteria	Response Rate (CR+PR)	Overall Survival
Chlorambucil vs. obs. ³²	Untreated, Stage A	76%	76% vs. 80% (5-year)
Chlorambucil vs. obs. ³³	Untreated, Stage A	68%	75% vs. 82% (5-year)
Chlorambucil vs. COP ³⁴	Untreated, B or C	59% vs. 61%	44% vs. 43% (5-year)
Chlorambucil vs. ChOP ³⁵	"Advanced"	89.5% vs. 75%	68% vs. 47% (5-year)

3.3 Evidence-Based Considerations for a Funding Population

While survival from diagnosis in CLL may exceed 10 years, survival from the onset of treatment is only 4 years and contrary to widely held belief, 70% of patients with CLL die of causes related to their disease. New, more effective treatments for patients with this disease are desperately needed. In contrast to initial treatment, there is no established treatment for patients with relapsed or refractory disease. The use of bendamustine in relapsed/refractory CLL was reviewed by pCODR previously (in December 2012).

3.4 Other Patient Populations in Whom the Drug May Be Used

Bendamustine has been evaluated in clinical trials for a variety of other malignancies including breast and lung cancer, but is not yet approved in any country for those indications.

4 SUMMARY OF PATIENT ADVOCACY GROUP INPUT

The following patient advocacy groups provided input on bendamustine (Treanda) for Chronic Lymphocytic Leukemia (CLL) and their input is summarized below:

- The Leukemia and Lymphoma Society of Canada
- The CLL Patient Advocacy Group

The Leukemia and Lymphoma Society of Canada conducted an anonymous survey to gather information about patient and caregiver experiences with Chronic Lymphocytic Leukemia (CLL). The survey was divided into four components, including the patient experience with CLL, current therapies used to treat CLL, the caregiver experience, and the patient experience or expectations for bendamustine. Survey respondents provided answers online, by phone, in writing, or in person. Additional information was gathered through printed sources.

The CLL Patient Advocacy Group (CLL PAG) designed and conducted an online survey to gather information about the patient and caregiver experience with CLL and the drug under review. The online survey was promoted on the CLL Patient Advocacy Group website, the CLL Canada website, as well as, various other discussion boards and websites dedicated to CLL. A total of 177 respondents participated in the survey. Due to the rarity of CLL and difficulties in identifying Canadian patients with experience with bendamustine, participation was requested from Canadian patients, as well as, patients from other countries. Of the 177 respondents to the survey, 70 patients were from Canada, 84 patients were from the United States, 9 patients were from Australia, 8 patients were from the United Kingdom, and there was one patient each from Belgium, India, France, Brazil, New Zealand, and Germany. In addition, additional background information on CLL and CLL treatments was gathered from the CLL PAG and CLL Canada websites.

From a patient perspective, additional drug therapies for the treatment of CLL which enable the patient to have a choice in their therapy, is an important aspect when consideration is given to treatment. In addition, patients want treatment options that will extend their life and bring about complete remission of the disease, while also allowing them to enjoy a good quality of life. Patients indicate they would be willing to tolerate the side effects of a new therapy, even significant side effects, if the side effects disappear after treatment is complete and if there is an improvement in their quality of life for a substantial length of time afterwards. In addition, patients also express a desire to have a treatment option that does not acquire or develop resistance, so the patient may be able to receive repeat treatments without having to worry about the therapy becoming less effective due to resistance.

Please see below for a summary of specific input received from the patient advocacy groups.

4.1 Condition and Current Therapy Information

4.1.1 Experiences patients have with Chronic Lymphocytic Leukemia (CLL)

Patient advocacy group input highlights that CLL is the most commonly diagnosed leukemia in Canada, although it is still considered to be an orphan disease in other countries, such as the United States or in Europe. Input from patients indicates that CLL is generally a disease of the older population, with most patients with CLL typically being diagnosed in their 60's and 70's. However, input from patients also points out that it is possible for CLL to be diagnosed in younger patients as well.

Input from patient advocacy groups indicates that for some patients, CLL is a chronic, slow-progressing cancer, and patients may live for many years before they require any drug treatment, if they even require treatment at all. However, some patients with CLL will progress more quickly and require treatment earlier.

Patients with CLL report that fatigue is one of the most common symptoms experienced and it can have a significant impact upon their quality of life. Patients may be unable to continue with their current workload and report having to retire at an earlier age than they anticipate due to the fatigue. Patients also indicate that fatigue prevents them from being able to perform household duties, and as a result, they are unable to maintain their home to the same degree as before their diagnosis. In addition, patients convey that the fatigue they experience limits their social connectivity, as they are too tired to socialize and as a result, they end up spending a lot of time alone. Patients responding to the CLL PAG survey report that fatigue and lack of energy is the most significant symptom of CLL that they deem as being important to control and manage.

Many patients with CLL also report that they experience feelings of depression, stemming from the knowledge that they have an incurable illness with a widely variable lifespan, and the inability to fulfill many life goals due to their lack of energy. Patients also report experiencing feelings of fear and worry, as they are uncertain of their future. Patients with CLL are cognizant of the effect that their illness has on their family and friends, and indicate that their diagnosis places a burden on others to care for them. Patients responding to the CLL PAG survey report that depression, stress, and psychological stress are the second-most significant symptoms of CLL that they deem important to control and measure.

Input from the patient advocacy groups also identify that patients with CLL have an increased susceptibility to infections, such as shingles or pneumonia, as a result of having a compromised immune system. Consequently, patients express that they often have to restrict their participation in social groups due to the fear of contracting an illness and often have to restrict any travel plans. Input also reports that many patients avoid long-term planning because they never know how they will feel.

In addition to the symptoms noted above, patients with CLL also indicate they may experience low platelets, enlarged lymph nodes, increased white cell count, night sweats, unexplained fevers, low immunoglobulin levels, aches, pains, enlarged spleen, weight loss and respiratory issues. . Patients responding to the CLL PAG survey also express that it is important to control and manage these symptoms.

4.1.2 Patients' Experiences with Current Therapy for Chronic Lymphocytic leukemia (CLL)

Patient advocacy group input indicates that current treatments for CLL are life-extending, but are not curative. With the treatments that patients receive, they have a period of remission, but the disease does return. Patients report that certain treatments may be repeated, but they usually experience shorter periods of remission due to the development of resistance.

Patients note that CLL is not a cancer that is easier to treat if caught early, therefore many patients with a diagnosis of CLL begin with an active watch and wait approach, where patients wait for their symptoms to progress and start causing significant problems prior to starting any therapy. Patients express that this approach can be difficult to deal with, as many patients are used to the concept that you start treatment right away after you have been diagnosed with cancer. Patients report that it is emotionally difficult to know that there is a cancer growing within them that must progress before they can begin to receive treatment.

Once medical interventions are required for the treatment of CLL, patients indicate there are several different therapies available, including chemotherapy agents such as fludarabine, chlorambucil, or cyclophosphamide, as well as, monoclonal antibodies, such as rituximab. The combination of fludarabine, cyclophosphamide, and rituximab, known as FCR, was noted by patient groups to be the gold standard for the treatment of CLL. However, patient input also pointed out that FCR is quite toxic and can leave patients in a greater immune-compromised state. Other side effects that patients indicate may occur with chemotherapy include hair loss, extreme fatigue, infections, nausea, and anemia. Although patients report that the side effects of treatment can be awful, patients also note that they go away and patients feel much better once they finish therapy and it is successful, as they have an increase in their energy level and a better quality of life. Patients also express that they are willing to endure negative side effects if it means having more quality years of life afterwards.

Patient advocacy group input also indicates that some patients, such as those who are younger or high-risk, may have the option of receiving an allogeneic stem cell transplant. In addition, some patients may be eligible to participate in a clinical trial, and this is often a way for patients to receive emerging drug therapies while waiting for their province to fund a drug that has been approved by Health Canada. Unfortunately, patient input highlights that many clinical trials often restrict enrollment to those patients who meet stringent criteria and have access to a cancer center participating in the clinical trial, and therefore, not all patients can access new drug therapies via clinical trials.

Patient input reveals that patients who start to receive treatment for CLL often have to travel to the hospital for therapy administration and physician visits, which can lead to these patients incurring additional financial costs.

Many patients express feelings of frustration that there is currently no standard of practice for CLL in Canada, and the treatment that a patient will receive may depend upon which province they reside in. In particular, patients express concern that there is unequal coverage of rituximab across the country. Patients without rituximab

coverage must pay for the treatment on their own if they wish to receive it and for some patients, the cost may be prohibitory and they do not receive the treatment.

Patients also express the importance of having additional choices for their treatment. In the CLL PAG survey, a majority of patients responding indicates that it would be very important to have choice in a therapy. In addition, patients feel that more treatment options need to be available for the treatment of CLL, such as bendamustine.

4.1.3 Impact of Chronic Lymphocytic Leukemia and Current Therapy on Caregivers

Patient advocacy group input indicates that the impact of this condition on caregivers can be significant, both prior to the patient receiving treatment and during the treatment itself. Caregivers may experience an emotional, financial and time impacts. Caregivers report that there can be a permanent change in how their household functions once a patient receives a CLL diagnosis.

Caregivers are often responsible for performing additional tasks around the home that were once shared or assumed completely by the patient and they may have to assume more of the financial burden as patients may have to stop working earlier than anticipated. In addition, caregivers have to assume the additional costs of providing care, and in particular, they may have to reduce their work hours to help provide care. Patients diagnosed with CLL who have young families are facing an additional burden of finding child care. Caregivers indicate that their social support system is reduced as they choose to stay with the patient who is often times not able to have the same level of social activity as in the past due to fatigue. In addition, caregivers must try to limit the normal activities and interactions of the patient with family and friends to try to prevent the CLL patient from developing infections.

Caregivers also indicate that they worry about the wellbeing of the patient, as well as, the uncertainty of the disease and if it will progress. Caregivers report feelings of anxiety and stress.

4.2 Information about the Drug Being Reviewed

4.2.1 Patient Expectations for and Experiences To Date with bendamustine (Treanda)

Input from patients without direct experience with bendamustine for CLL indicates that patients with CLL are seeking more treatment options for their condition. Patients are aware that they have an incurable disease and that the currently available treatment options only work for a limited amount of time due to drug resistance and therefore, patients want more choices and rate more treatment options as being very important. In addition, patients want treatment options that will extend their life and bring about complete remission of the disease, while also allowing them to enjoy a good quality of life. A majority of patients responding to the CLL PAG

survey indicate that that when considering bendamustine as a treatment for CLL, it is important to bring about complete remission.

Patients indicate that they would be willing to tolerate the side effects of a new therapy, even significant side effects, if the side effects disappear after treatment is complete and there is an improvement in their quality of life for a substantial length of time afterwards.

Patients also express a desire to have a treatment option that does not acquire or develop resistance, such as the case with the currently available treatment options. Patients convey that they have heard reports that indicate that patients do not develop resistance to bendamustine the way they do with other treatments and this is important to those patients who require repeat treatments for their condition. Patient input highlights that for patients who were previously treated, they need another treatment option that will not have a decreased efficacy due to resistance.

Input from the Leukemia and Lymphoma Society of Canada indicates feedback was not received from patients currently using bendamustine. Input from CLL PAG indicates that 18 patients who responded to their survey report having direct experience with bendamustine.

Approximately half of patients with direct experience with bendamustine indicate that the infusion schedule was easier to manage with bendamustine in comparison to the administration of other IV treatments for CLL, while the other half of patients indicate that that the infusion schedule was about the same as the administration of other IV treatments for CLL.

When patients with direct experience with bendamustine were asked in the CLL PAG survey which symptoms have shown a great improvement with bendamustine in comparison to other treatments for CLL, eleven of the 14 patients who answered this question report having greater symptomatic improvement with bendamustine in comparison to other treatments. Two patients report having a similar symptomatic improvement, and one patient reports that bendamustine was not effective in treating his/her CLL. When patients were asked in the CLL PAG survey what the effects of bendamustine have been on their CLL, eleven of the 13 patients who answered this question report a positive response to bendamustine with respect to white blood cell counts, and/or a reduction in node size, and/or a reduction in fatigue, whereas two patients report that bendamustine was not effective in treating their CLL.

When patients were asked to rate their quality of life (QoL) on a scale of 1 (low QoL/severely impacted) to 10 (high QoL/normal living) while receiving bendamustine, responses were mixed. Fifteen patients with with bendamustine experience responded to this question in which five patients rank their QoL as 8 or higher; six patients rank their QoL between 5 and 7 and four patients ranking their QoL as 3 or 4 while receiving bendamustine. However, a majority of patients responding to the CLL PAG survey indicate that they would consider receiving bendamustine again for that second-line treatment of CLL after receiving it for the first-line treatment.

Overall, most patients in the survey would rank their experience with bendamustine the same as, or better, than other treatments for CLL. A minority of patients would rank their experience with bendamustine as worse than that with other treatments.

4.3 Additional Information

The Leukemia and Lymphoma Society of Canada indicates that they appreciate the opportunity to ensure that the patient voice is heard during the review process, but express that timelines are rather short, which can make it difficult to gather and review the necessary information. In addition, the patient group points out that it can be difficult to find patients with direct experience with the drug under review within the time constraints due to a number of factors, such as privacy or physician schedules.

5 SUMMARY OF PROVINCIAL ADVISORY GROUP (PAG) INPUT

The following issues were identified by the Provincial Advisory Group (PAG) as factors that could affect the feasibility of implementing a funding recommendation for bendamustine (Treanda) for the treatment of Chronic Lymphocytic Leukemia (CLL). This input was collected at the outset of the pCODR review.

The Provincial Advisory Group includes representatives from provincial cancer agencies and provincial and territorial Ministries of Health participating in pCODR. The complete list of PAG members is available on the pCODR website (www.pcodr.ca).

Overall Summary

Input on the bendamustine (Treanda) review was obtained from all nine provinces (Ministries of Health and/or cancer agencies) participating in pCODR. From a PAG perspective, the combination of rituximab, fludarabine and cyclophosphamide was identified as the main comparator to bendamustine and comparative information between the two treatments with respect to side effect profile or treatment outcomes would be important to know. PAG also identified that there is a potential for bendamustine to be used in other lines of therapy for CLL, such as the relapsed or refractory setting. PAG noted that information on the use of bendamustine in these other lines of therapy (i.e. relapsed/refractory setting) would be useful. The use of bendamustine in relapsed/refractory CLL has been previously reviewed by pCODR previously (in December 2012).

Please see below for more detailed PAG input on individual parameters.

5.1 Factors Related to Comparators

PAG recognized that chlorambucil was previously the standard of care for the first-line treatment of CLL when the pivotal trial for bendamustine was designed and as such, was the most appropriate comparator at that time.

PAG noted that the combination of rituximab, fludarabine and cyclophosphamide (FC-R) is the current first-line treatment option for medically fit patients with CLL; however, if there are no comparative trials between bendamustine and this comparator, this may pose as a barrier to implementation of a funding decision for bendamustine. It was noted that rituximab is currently funded in some jurisdictions for this indication. PAG identified that any available comparative data with respect to side effect profile or treatment outcomes for these two treatments (i.e. FC-R and bendamustine) would be helpful. In addition, PAG recognized that bendamustine is a single agent treatment, which would likely be less complicated to administer compared to a multiple drug regimen such as FC-R.

PAG noted that chlorambucil would likely be the other main comparator to bendamustine in situations where FC-R treatment cannot be used.

If it were determined that bendamustine had a favourable efficacy and toxicity profile in relation to other comparators for CLL during the pCODR review, PAG identified that there may be significant market uptake of bendamustine, which would need to be factored into the budget impact.

5.2 Factors Related to Patient Population

As hematologic malignancies tend to be less common than solid tumors overall, PAG recognized that there may be small numbers of patients accessing bendamustine. However, it was also noted that jurisdictions may see more patients requesting bendamustine than anticipated due to its assumed improved tolerability compared with the FC-R regimen.

- 5.3 Although the Health Canada approved indication for bendamustine is in the first-line setting of CLL, PAG identified that there is potential for use in later lines of therapy, such as the relapsed or refractory setting. PAG noted that information on the use of bendamustine in other lines of therapy would be useful. The use of bendamustine in relapsed/refractory CLL has been previously reviewed by pCODR previously (in December 2012).

5.4 Factors Related to Accessibility

PAG identified several potential accessibility issues with respect to bendamustine treatment. It was noted that bendamustine is administered intravenously and as such, specialized chemotherapy centers would be likely be required for appropriate administration, which would not be required with an oral agent such as chlorambucil. In addition, bendamustine is administered on two consecutive days out of a 28-day cycle. Compared to orally administered chlorambucil, patients will have to travel for treatment and spend two days at specialized treatment centers to receive bendamustine, which may pose as a barrier to funding implementation.

PAG recognized that wastage is a potential concern with bendamustine as it only comes in two different vial formats with no preservative. It was noted that some hospitals may not be willing to administer bendamustine if wastage is thought to be a significant problem as they would not be reimbursed for wastage costs and would have to incur the additional costs of the wasted product.

5.5 Factors Related to Dosing

PAG noted that bendamustine is also indicated for the treatment of indolent non-Hodgkin's lymphoma (iNHL) with a different dosage regimen than that indicated for CLL (i.e. 120mg/m² every 21 days for NHL versus 100mg/m² every 28 days for CLL). PAG recognized that there may potentially be confusion in dosing between the two different indications which could lead to errors.

PAG noted that there may be a potential for bendamustine to be delivered in non-tertiary care areas; however, this may depend on the threshold for cost of drug wastage. Although it was noted that toxicity may preclude bendamustine administration in some smaller centers, it was also noted that bendamustine appeared to be well tolerated in the pivotal trial and approximately 90% of patients were given the planned dose of medication.

5.6 Factors Related to Implementation Costs

PAG anticipated that the price of bendamustine would be higher than that of chlorambucil, which would pose as a barrier to the implementation of funding this therapy.

PAG recognized that drug wastage could be an issue with bendamustine as there will likely only be two vial sizes available (25mg vial and 100mg vial as in the US) and there is no preservative. The product monograph indicates that the final admixture is stable for 24 hours under refrigeration or three hours at room temperature and partial vials are to be discarded. In some jurisdictions, hospitals are not reimbursed for wastage costs and would have to incur the additional costs of the wasted product which would be a barrier to implementation.

As bendamustine is an intravenously administered product, PAG noted that there would be chemotherapy chair utilization, increased pharmacy preparation time and an increased need for various resources. PAG identified that difficulties may be encountered when reconstituting bendamustine, as the product monograph indicates that it may take five minutes for complete dissolution of the particles, and this could slow down production time in the pharmacy. Also, it was noted that there may be additional drug wastage if the particles remain in the product after it has been prepared and the allotted five minute waiting period passes.

PAG also recognized that there may be additional costs associated with bendamustine treatment, such as the cost of growth factors or hospitalization costs if a patient developed febrile neutropenia.

If it were determined that bendamustine had a favourable toxicity profile in relation to other comparators for CLL during the pCODR review, there may potentially be cost savings as a result of not having to treat those toxicities.

5.7 Other Factors

No additional input was received.

6 SYSTEMATIC REVIEW

6.1 Objectives

To evaluate the effect of bendamustine, either as a single agent or in combination with other chemotherapeutic agents on patient outcomes compared to appropriate comparators in the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).

See Table 8 in Section 6.2.1 for outcomes of interest and appropriate comparators.

Note: Supplemental Questions most relevant to the pCODR review and to the Provincial Advisory Group were identified while developing the review protocol and are outlined in section 7.

6.2 Methods

6.2.1 Review Protocol and Study Selection Criteria

The systematic review protocol was developed jointly by the Clinical Guidance Panel and the pCODR Methods Team. Studies were chosen for inclusion in the review based on the criteria in the table below. Outcomes considered most relevant to patients, based on input from patient advocacy groups are those in bold. In addition, data on subgroup analyses by age, performance status, or CIRS score for the outcomes of interest were to be included in this review, if available.

Table 8. Selection Criteria

Clinical Trial Design	Patient Population	Intervention	Appropriate Comparators*	Outcomes
Previously untreated CLL				
Published or unpublished RCT	Patients with previously untreated CLL	Bendamustine 60-100 mg/m ² on days 1 and 2, every 28 days	FC-R Chlor +/- R Cyclo + pred CVP Cyclo+pred+dex +R	OS PFS Response QOL Adverse events Neutropenia FN Infection Rash - SJS, TENS Tumour lysis syndrome
[Abbreviations] Chlor=chlorambucil; CLL=chronic lymphocytic leukemia; CVP=cyclophosphamide, vincristine; prednisone; cyclo=cyclophosphamide; dex=dexamethasone; FC=fludarabine, cyclophosphamide; OS=overall survival; PFS=progression-free survival; pred=prednisone; QOL=quality of life; R=rituximab.				

*Standard and/or relevant therapies available in Canada (may include drug and non-drug interventions)

¹A mixed design was defined as a trial with a dose-escalation phase followed by an efficacy-determining phase in which the study intervention was administered at the same dose and schedule to all patients (generally the maximum tolerated dose determined in the dose-escalation phase).

6.2.2 Literature Search Methods

The literature search was performed by the pCODR Methods Team using the search strategy provided in Appendix A.

Published literature was identified by searching the following bibliographic databases: MEDLINE (1946-) with in-process records & daily updates via Ovid; EMBASE (1980-) via Ovid; The Cochrane Central Register of Controlled Trials (2012, Issue 8) via Wiley; and PubMed. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were bendamustine (Treanda) and CLL.

Methodological filters were not applied to limit retrieval to specific trial designs. Retrieval was not limited by publication year. Retrieval was not limited by language.

The search is considered up to date as of September 10, 2012.

Grey literature (literature that is not commercially published) was identified by searching the websites of regulatory agencies, clinical trial registries and relevant conference abstracts. Searches of conference abstracts were limited to the last five years. Searches were supplemented by reviewing the bibliographies of key papers and through contacts with the Clinical Guidance Panel. In addition, the manufacturer of the drug was contacted for information regarding unpublished studies.

6.2.3 Study Selection

One member of the pCODR Methods Team selected studies for inclusion in the review according to the predetermined protocol. All articles considered potentially relevant were acquired from library sources. Two members of the pCODR Methods Team independently made the final selection of studies to be included in the review and differences were resolved through discussion.

Included and excluded studies (with reasons for exclusion) are identified in section 6.3.1.

6.2.4 Quality Assessment

Assessment of study bias was performed by one member of the pCODR Methods Team with input provided by the Clinical Guidance Panel and other members of the pCODR Review Team. SIGN-50 Checklists were applied as a minimum standard. Additional limitations and sources of bias were identified by the pCODR Review Team.

6.2.5 Data Analysis

No additional data analyses were conducted as part of the pCODR review.

6.2.6 Writing of the Review Report

This report was written by the Methods Team, the Clinical Guidance Panel and the pCODR Secretariat:

- The Methods Team wrote a systematic review of the evidence and summaries of evidence for supplemental questions.
- The pCODR Clinical Guidance Panel wrote a summary of background clinical information and the interpretation of the systematic review. The Panel provided guidance and developed conclusions on the net overall clinical benefit of the drug.


The pCODR Secretariat wrote summaries of the input provided by patient advocacy groups and by the Provincial Advisory Group (PAG).

6.3 A) Results - Previously Untreated Chronic Lymphocytic Leukemia

6.3.1 A) Literature Search Results

Of the 30 potentially relevant reports identified, 15 reports of seven unique studies were included in the pCODR systematic review that investigated the use of bendamustine in patients with CLL^{1-9,36-41} and 15 articles were excluded (Figure 1). Studies were excluded because they were reviews⁴²⁻⁴⁴, editorials⁴⁵, the outcomes were not reported for the population of interest⁴⁶, the trial utilized only a dose-escalation design⁴⁷⁻⁴⁹, abstract publications of single-arm trials⁵⁰⁻⁵⁴, or they were published in German⁵⁵ or Polish⁵⁶. Of the 15 reports included in the pCODR systematic review, nine reports of one study pertained to the use of bendamustine in patients with previously untreated CLL. Three reports on bendamustine in patients with previously untreated CLL from the United States Food and Drug Administration (US FDA) were identified.^{20,57,58} Additional information was obtained from the submission by the manufacturer to pCODR.¹⁸ Information on the trial design was also obtained from the ClinicalTrials.gov record.⁵⁹

Figure 1. QUOROM Flow Diagram for Included and Excluded Studies of Bendamustine in CLL.



Notes: Additional data related to studies 02CLLIII were also obtained through requests to the Submitter by pCODR.⁶⁰ Six reports investigated the use of bendamustine in patients with relapsed or refractory CLL and are not discussed further in this report.³⁶⁻⁴¹ For further information on those studies, please see the Final Clinical Guidance Report for Bendamustine (Treanda) in Chronic Lymphocytic Leukemia (Relapsed/Refractory) November 29, 2012.

6.3.2 A) Summary of Included Studies

One randomized trial (study 02CLLIII) was identified that randomized patients with previously untreated CLL to either bendamustine or to chlorambucil.¹⁻⁹

6.2.6.1 A) Detailed Trial Characteristics

a) *Trials*

Only one study, 02CLLIII, met the inclusion criteria for this section of the review focused on previously untreated CLL (see Table 1).¹ Study 02CLLIII enrolled adult patients less than 75 years of age with previously untreated, Binet stage B or C CLL, confirmed by coexpression of CD5, CD23, and either CD19, CD20, or both. The study was conducted in 45 centers in eight countries in Europe and was industry-sponsored. The study was open-label: neither the patients nor the investigators were blinded to treatment assignment. The primary publication did not report the method used for randomization or masking of treatment allocation; however, the Health Canada review included in the pCODR submission noted that, an appropriate method of randomization was utilized.¹⁸ This was confirmed by the manufacturer at the Checkpoint Meeting.⁶⁰

The study had two co-primary outcomes. The first was overall response rate and the second was progression-free survival. Response assessment was conducted after three cycles of treatment using the criteria of the National Cancer Institute Working Group (NCI-WG) guidelines for CLL and had to be met for at least eight weeks. Patients were monitored at three-month intervals following the last treatment cycle. The original protocol required the investigators to conduct the response evaluations; however, these were inconsistently managed and an independent response assessment committee was established to assess response for all patients included in the third interim analysis as well as the final analysis (protocol change).²⁰ The final assessment of best response was conducted in a blinded fashion by the independent response assessment committee and classified as complete response, partial response, partial response with nodular involvement, stable disease, or progressive disease based on the NCI-WG criteria.¹ The definition of progression-free survival was not reported in the primary publication¹; however, the FDA medical and statistical reviews^{20,58} and the Product Monograph¹⁸ reported that progression-free survival was defined as the time from randomization to progressive disease or death from any cause. Secondary outcomes included time-to-progression, duration of remission, overall survival, rate of infections, and adverse events.

The 02CLLIII study investigators assumed overall response rates of 60% for the bendamustine arm and 30% for the chlorambucil arm, and median progression-free survival of 20 months in the bendamustine arm and 14 months in the chlorambucil arm. To obtain a power of 80% with a 2-tail test at $\alpha=0.05$, 42 patients per arm would be required for overall response and 326 patients total for progression-free survival. The sample size for a fixed sample design was estimated to be 350 patients.¹ The study investigators used a five-stage adaptive group sequential design with Pocock cut-offs of $\alpha=0.16$, with four planned interim analyses. At each interim analysis, overall response rate was tested first, and if significant, progression-free survival was then tested. At the second analysis, the prespecified stopping criteria had been reached; however, it was recommended that the study continue until 300 patients had been enrolled with no further interim analyses. The

third interim analysis was conducted after 305 patients had been enrolled and the Independent Data Monitoring Committee recommended that patient recruitment be stopped and a final analysis be conducted. Enrolment ceased in November 2006 with 319 patients enrolled.

Overall response was analyzed by Fisher's exact test, stratified by Binet stage.¹ Progression-free survival was analyzed by the log-rank test stratified by Binet stage and combined across study groups, as described by Lehmacher and Wassmer.⁵⁸ Kaplan-Meier curves were used to estimate progression-free survival statistics.

b) Populations

A total of 162 and 157 patients were randomized to bendamustine and chlorambucil, respectively. No notable differences in baseline patient characteristics were observed between the two treatment groups (see Table 9).

Table 9. Baseline Patient Characteristics in Study O2CLLIII¹

Characteristic	Bendamustine	Chlorambucil
n	162	157
Sex (%)		
Female	37.0	39.5
Male	63.0	60.5
WHO PS (%)		
Missing	1.9	3.2
0	69.8	65.0
1	26.5	28.7
2	1.9	3.2
Age (years)		
Mean	63.0	63.6
Standard deviation	7.5	8.8
Median	63.0	66.0
Minimum-maximum	45.0-77.0	35.0-78.0
Binet stage (%)		
B	71.6	70.7
C	28.4	29.3
B symptoms (%)		
Yes	49.4	50.3
No	50.0	47.1
Unknown	0.6	2.5
Lactate dehydrogenase (%)		
Normal	51.9	51.0
Out of normal ranges	45.1	42.0
Not done	3.1	3.8
Time from initial diagnosis to enrolment (months)		
Mean	18.8	24.6
Standard deviation	32.3	33.9

Notes: n=number of patients randomized; WHO PS=World Health Organization performance status.

c) Interventions

One hundred sixty-two patients were randomized to receive bendamustine at a dose of 100 mg/m²/d on days 1 and 2 of a 4-week cycle. One hundred fifty-seven patients were randomized to receive chlorambucil at a dose of 0.8 mg/kg (Broca's normal weight in kg; body weight being the height of patient in centimetres minus

100) on days 1 and 15 of a 4-week cycle. In individual cases the doses of chlorambucil could be divided on days 1 to 2 and days 15 to 16.¹

Patients were assessed for response at three weeks. Patients with no change were allowed to receive additional cycles at the discretion of the investigator to a maximum of 6 cycles. Patients with complete response or partial response received additional cycles up to a maximum of 6 cycles. Patients with progressive disease were withdrawn from the study.¹

Treatment was interrupted if platelet counts $<20 \times 10^9/L$, hemoglobin counts <7 g/dL, or the absolute neutrophil counts $<0.5 \times 10^9/L$. Doses were modified according to the NCI-WG guidelines if hematologic toxicities developed. For Common Toxicity Criteria grade 3 nonhematologic toxicities other than nausea and vomiting or alopecia, the dose was reduced by 50% or the patient withdrawn from the study at the investigator's discretion. If any grade 4 toxicity developed, the patient was withdrawn.¹

The median number of treatment cycles was six in both treatment arms. The mean number of cycles per patient was 4.9 cycles (standard deviation, 1.7) in both the bendamustine arm and the chlorambucil arm. At least one dose reduction was required in 54 (34%) of patients in the bendamustine arm and in 46 (31%) of patients in the chlorambucil arm. The primary reasons for dose reductions in both treatment groups were neutropenia and thrombocytopenia. Adherence to the dosing schedule was high with 90% of the planned bendamustine dose and 95% of the planned chlorambucil dose administered.¹

d) Patient Disposition

The primary publication by Knauf et al 2009, reported that of 319 randomized patients, seven were not treated (six in the chlorambucil arm and one in the bendamustine arm).¹ That publication reported no further data on patient disposition.

The pCODR submission provided details of patient disposition for all 319 randomized patients (see Table 10).¹⁸

Table 10. Patient Disposition in Study 02CLLIII Obtained From pCODR Submission.¹⁸

	Bendamustine (n)	Chlorambucil (n)
N Randomized	162	157
Received allocated intervention	161	151
Discontinued intervention	39	23
Protocol violation	1	1
Unacceptable toxicity	15	5
Investigator's decision	2	5
Subject refusal	9	6
Lack of compliance	1	1
Death	1	3
Risk/benefit assessment no longer acceptable	3	0
Other reasons	7	2
Lost to follow-up	0	1

Notes: n=number of patients.

The U.S. FDA Medical Review noted that eight patients in the bendamustine arm and three in the chlorambucil arm were lacking a phenotypic confirmation of diagnosis.²⁰ Out of all 319 randomized patients, one patient in the bendamustine

arm and six patients in the chlorambucil arm did not receive the allocated intervention.¹⁸ The disposition of the seven patients who did not receive the allocated intervention is not publicly available.

e) Limitations/Sources of Bias

Neither the investigators nor the patients were blinded to treatment assignment, likely due to the different routes of administration of the two agents, bendamustine (i.v.) and chlorambucil (oral). Importantly, the investigators amended the trial protocol to include blinded tumour assessments conducted by an independent tumour assessment committee¹, therefore the risk of bias in the outcome assessments (response and progression-free survival) is likely low.

A total of up to 18 patients had protocol violations: eleven patients did not meet the diagnostic confirmation required in the protocol, and seven patients did not receive the allocated intervention. As these patients represent, at most, 5.6% of the study population, they most likely had little impact on the study results.

6.2.6.2 A) Detailed Outcome Data and Summary of Outcomes

Efficacy Outcomes

A total of 319 patients (162 patients in the bendamustine arm and 157 patients in the chlorambucil arm) were included in the ITT efficacy analysis.¹ Table 2 summarizes the key efficacy outcomes for the 02CLLIII Study.

Overall Survival


In the initial 2009 full publication, Knauf et al reported that additional follow-up time would be required in order to comment on overall survival.¹ A total of 72 of 319 patients (31 in the bendamustine arm and 41 in the chlorambucil arm) died during follow-up. Median follow-up was 35 months (minimum-maximum, 1-68 months).¹ Death due to CLL was reported for 13 patients in the bendamustine arm and 21 patients in the chlorambucil arm.

In 2012, Knauf et al published updated results from the 02CLLIII study.² The analysis was conducted in May 2010 on the final intent-to-treat population (N=319). After a median follow-up of 54 months, a total of 132 patients had died, with the date of death unknown for 26 patients (bendamustine, n=15; chlorambucil, n=11). The date of death for the 26 patients was censored using the date of the last contact upon which the patient was last documented to be alive. No statistically significant difference in overall survival was observed between the two treatment groups: median overall survival had not yet been reached in the bendamustine group and was 78.8 months in the chlorambucil group, with a HR of 0.77 (95% CI 0.52-1.12).² In addition, the authors reported no statistically significant differences in overall survival for the bendamustine arm compared to the chlorambucil arm for the following subgroup analyses: Binet stage B or C, age (>65 years or ≤65 years), and response (objective response, stable disease or progressive disease).²

Progression-free Survival

Median progression-free survival was 21.6 months in the bendamustine arm compared to 8.3 months in the chlorambucil arm ($p < 0.0001$); no hazard ratio data were reported in the primary publication.¹ However, the Product Monograph reported a hazard ratio (HR) of 0.26, $p < 0.0001$ for the progression-free survival analysis.¹⁸ See Figure 2 for the Kaplan-Meier survival curves for progression-free survival reported in the primary publication. There were a total of [REDACTED] events ([REDACTED] in the bendamustine arm and [REDACTED] in the chlorambucil arm) at the date of the analysis.¹⁸

Figure 2. Progression-free Survival Based on the Independent Tumour Assessment and as Reported in the Primary Publication of Study 02CLLIII.¹



Knauf et al also reported that the difference in progression-free survival was observed in the subgroup of patients with Binet stage B (bendamustine arm, median 21.4 months vs. chlorambucil arm, median 9.0 months) and Binet stage C (bendamustine, median 25.4 months vs. chlorambucil, 6.3 months), although no p-values or hazard ratios were reported.¹ A 2009 ASH abstract reported by Knauf et al noted that a consistent effect in favour of bendamustine compared to chlorambucil was observed for progression-free survival in both Binet stage B and C disease, and in patients older than 65 years and in those younger than 65 years.⁴ No data were reported.

A sensitivity analysis of progression-free survival was conducted using a computer algorithm to rigorously apply the NCI-WG criteria to the entire data study set.^{20,58} Progression-free survival based on this analysis resulted in a median progression-free survival of 17.6 months in the bendamustine arm compared to 5.7 months in the chlorambucil arm, HR=0.269, 95% CI 0.169 to 0.428, $p < 0.0001$.^{20,58}

Knauf et al reported that the progression-free survival analysis was relatively unchanged in the May 2010 analysis from the original final analysis.² Median progression-free survival was 21.2 months in the bendamustine arm compared to 8.8 months in the chlorambucil arm (HR adjusted for Binet stage was 0.35, 95% CI 0.27-0.46; $p < 0.0001$).²

Response

The overall response rate was statistically significantly different for bendamustine compared to chlorambucil (68% vs. 31%; $p < 0.0001$).¹ Higher rates for complete response and nodular partial response were observed in the bendamustine arm than in the chlorambucil arm (no-p-values were reported; see Table 11).

Table 11. Proportion of Patients with Response in Study 02CLLIII.¹

Response Type	Binet Stage B		Binet Stage C		Total	
	BEN	CLB	BEN	CLB	BEN	CLB
N rand	116	111	46	46	162	157
Response Rate by Independent Tumour Assessment (%)						
CR	35	3	20	0	31	2
nPR	12	4	7	0	11	3
OR	71	34	61	22	68*	31*
Response Rate by Computer Algorithm (%)						
CR	NR	NR	NR	NR	9	<1
OR	NR	NR	NR	NR	68*	32*

Notes: BEN=bendamustine; CLB=chlorambucil; CR=complete response; N=number of patients; nPR=nodular partial response; NR=not reported; OR=overall response; rand=randomized.

*Statistically significant difference, $p < 0.0001$.


A sensitivity analysis of response rates was conducted using a computer algorithm to apply the NCI-WG criteria for response. The analysis led to almost no change in the rates of overall response; however, the rate of complete response decreased from 31% to only 9% in the bendamustine arm.¹⁸ The most common reason for downgrading of a complete response was a missing, indeterminate, or premature bone marrow assessment.

Knauf et al reported, in abstract form, that the overall response rate for patients aged less than 65 years was not statistically significantly different than patients aged more than 65 years: bendamustine arm, 71.6% vs. 63.5%; $p > 0.3$; chlorambucil arm, 28.4% vs. 32.5%; $p > 0.6$.⁴

Quality of Life

Quality of life was not reported in detail.¹ The Health Canada review within the pCODR submission¹⁸ and an ASH abstract reported by Knauf et al³ reported some quality of life details regarding study 02CLLIII.

Quality of life was measured using the European Organization for the Research and Treatment of Cancer (EORTC) QLQ-30 instrument.



No data were reported.

Knauf et al³ reported that no differences in baseline quality of life scores were observed between the treatment arms and that after completion of study treatment, no differences were observed with respect to physical, social, emotional, and cognitive functioning. Self-assessment of global health status showed no differences. No data were reported.

Harms Outcomes

The safety population includes all 312 treated patients (161 patients in the bendamustine arm and 151 patients in the chlorambucil arm).¹ Table 2 summarizes the key harms outcomes.

Hematological adverse events can be found in Table 12. The rates of any grade and grade 3/4 neutropenia, anemia, leucopenia, and lymphopenia were all higher in the bendamustine arm than in the chlorambucil arm. It was not reported whether those differences were statistically significant. G-CSF was used at the discretion of the investigator in 23 of 783 (2.9%) bendamustine cycles and in 2 of 733 (0.3%) chlorambucil cycles.¹ Erythropoietin was administered in 0.5% of bendamustine cycles and in 0.3% of chlorambucil cycles.

Table 12. Proportion of Patients with Hematological Adverse Events in Study O2CLLIII.¹

Intervention	n	Neutropenia		Thrombocytopenia		Anemia		Leukopenia		Lymphopenia	
		any	G 3/4	any	G 3/4	any	G 3/4	any	G 3/4	any	G 3/4
BEN	161	27.3	23.0	24.8	11.8	21.7	2.5	17.4	14.3	6.2	6.2
CLB	151	13.9	10.6	20.5	7.9	13.9	0	3.3	1.3	0.7	0

Notes: BEN=bendamustine; CLB=chlorambucil; n=number of patients.

The rates of non-hematological adverse events of any grade that occurred in more than 10% of patients can be found in Table 13. Eight-nine percent of patients in the bendamustine arm and 81% of patients in the chlorambucil arm experienced at least one adverse event of any Grade.¹ The rates of nausea, vomiting, pyrexia, rash and infections were higher in the bendamustine arm than in the chlorambucil arm. Rash and infection were included as they were identified a priori in the pCODR clinical guidance report review protocol as adverse events of interest. The rates of grade 3 or 4 non-hematological adverse events were similar in both treatment arms (see Table 14). Of note, 55% of patients in the bendamustine arm experienced at least one Grade 3 or 4 adverse event compared to 32% of patients in the chlorambucil arm (see Table 2); however, no information is available on whether the difference is statistically significant.¹⁹

Table 13. Proportion of Patients with Non-Hematological Adverse Events of Any Grade in Study 02CLLIII.¹

Intervention	n	Nausea	Vomiting	Pyrexia	Rash	Nasopharyngitis	Infection
BEN	161	19.3	15.5	24.8	9.3	6.8	6.2
CLB	151	13.9	6.6	5.3	4.6	7.3	1.3

Notes: BEN=bendamustine; CLB=chlorambucil; n=number of patients.

Table 14. Proportion of Patients with Grade 3 or 4 Non-Hematological Adverse Events in Study 02CLLIII.¹

Intervention	N	Nausea	Vomiting	Diarrhea	Pyrexia	Fatigue	Hyper-sensitivity	Infection	Hyper-uricemia	Cough	Rash
BEN	161	0.6	1.2	1.2	1.9	1.2	1.2	1.9	1.9	0.6	2.5
CLB	151	0.7	0	0	1.3	0	0	0	0	0.7	2.0

Notes: BEN=bendamustine; CLB=chlorambucil; n=number of patients.

Tumour lysis syndrome occurred in two patients in the bendamustine arms after the first cycle. Neither was fatal and both patients continued treatment.¹⁻⁹

The rates of febrile neutropenia, Stevens-Johnson syndrome, and toxic epidermal necrolysis were not reported in the publicly available literature. The manufacturer indicated that no events were reported for Stevens-Johnson syndrome or toxic epidermal necrolysis.⁶⁰ The manufacturer also indicated that febrile neutropenia, defined as pyrexia (any grade) coincident with a period of grade 3 or 4 neutropenia without clinical or microbiological documentation of infection, occurred in [REDACTED] ([REDACTED]) in the chlorambucil arm and in [REDACTED] ([REDACTED]) in the bendamustine arm.⁶⁰

The U.S. FDA medical review reported that four patients died within 30 days of taking the study drug, one patient in the bendamustine arm and three in the chlorambucil arm.²⁰ The review noted that the one death in the bendamustine arm was unlikely due to bendamustine.

Ongoing Trials

Three ongoing RCTs were identified investigating the use of bendamustine in patients with CLL through a search of clinical trial registries: NCT00769522, NCT01657955, and NCT01109264. Details of the trials can be found in Tables 16 to 18.

Table 16. Study NCT00769522: Phase III trial of combined immunochemotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) versus bendamustine and rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL10).⁶¹

Trial Design	Inclusion Criteria	Interventions and Comparators	Outcomes
<p>Study NCT00769522</p> <p>Open-label, active control, multicenter randomized phase III trial.</p> <p>Start date: September 2008</p> <p>Expected completion date: July 2011</p> <p>Estimated enrolment: 564</p> <p>Sponsor: German CLL Study Group.</p> <p>Collaborators: Roche Pharma AG, Mundipharma</p>	<p>Confirmed diagnosis of B-cell CLL</p> <p>Binet stage C or A/B requiring treatment</p> <p>Binet B or A with one of more of:</p> <p>B-symptoms</p> <p>Progressive lymphocytosis</p> <p>Evidence of progressive marrow failure</p> <p>Massive progressive or painful splenomegaly or hypersplenism</p> <p>Massive lymph nodes</p> <p>No prior CLL-specific chemotherapy, radiotherapy, and/or immunotherapy</p> <p>WHO PS 0-2</p>	<p>Two arms:</p> <p>Bendamustine i.v. d1,2 + rituximab d0 cycle 1 then d1 of cycles 2-6, every 28 days for 6 cycles—no further details available.</p> <p><i>Or</i></p> <p>Fludarabine i.v. d1-3 + cyclophosphamide i.v. d1-3 + rituximab d0 of cycle 1 then d1 of cycles 2-6, every 28 days for 6 cycles—no further details available.</p>	<p><u>Primary outcomes:</u></p> <p>Progression-free survival</p> <p><u>Secondary outcomes:</u></p> <p>Minimal residual disease</p> <p>Duration of remission</p> <p>Event-free survival</p> <p>Overall survival</p> <p>Overall response rate</p> <p>Adverse events</p> <p>Quality of Life</p>

Available from: <http://clinicaltrials.gov/ct2/show/NCT00769522?term=nct00769522&rank=1>

Table 17. Study NCT01657955: Study of bendamustine hydrochloride injection versus chlorambucil in previously untreated chronic lymphocytic leukemia patients.⁶²

Trial Design	Inclusion Criteria	Interventions and Comparators	Outcomes
<p>Study NCT01657955</p> <p>Open-label, active control, randomized phase III trial.</p> <p>Start date: January 2011</p> <p>Expected completion date: October 2013</p>	<p>Confirmed diagnosis of CLL</p> <p>Binet stage B or C, or symptomatic stage A</p> <p>Treatment required to control disease</p> <p>No prior or no standard treatment for CLL</p>	<p>Two arms:</p> <p>Bendamustine i.v. 100 mg/m²/d on days 1 and 2, every 28 days, up to 6 cycles.</p> <p><i>Or</i></p> <p>Chlorambucil 0.4 mg/kg/d on days 1 and 2, every 28 days, up to</p>	<p><u>Primary outcomes:</u></p> <p>Overall response</p> <p><u>Secondary outcomes:</u></p> <p>Progression-free survival</p> <p>Duration of response</p> <p>Overall survival</p>

Trial Design	Inclusion Criteria	Interventions and Comparators	Outcomes
Estimated enrolment: 96 Sponsor: Shandong Lanjin Pharmaceuticals Co. Ltd.	ECOG PS 0-2	6 cycles.	

Available from: <http://clinicaltrials.gov/ct2/show/NCT01657955?term=NCT01657955&rank=1>.

Table 18. Study NCT01109264: Study of bendamustine hydrochloride injection versus chlorambucil in previously untreated chronic lymphocytic leukemia patients.⁶³

Trial Design	Inclusion Criteria	Interventions and Comparators	Outcomes
Study NCT01109264 Open-label, active control, randomized phase II trial. Start date: March, 2010 Expected completion date: December 2013 Estimated enrolment: 144 Sponsor: Jiangsu Simcere Pharmaceutical R&D Co. Ltd.	Confirmed diagnosis of CLL according to NCI working group criteria Binet stage B or C No prior treatment for CLL ECOG PS 0-2	Two arms: Bendamustine i.v. 100 mg/m ² /d on days 1 and 2, every 28 days, up to 6 cycles. <i>Or</i> Chlorambucil 0.4 mg/kg/d on days 1 and 2, every 28 days, up to 6 cycles.	<u>Primary outcomes:</u> Overall response <u>Secondary outcomes:</u> Progression-free survival Duration of response Overall survival Adverse events

Available from: <http://clinicaltrials.gov/ct2/show/NCT01109264?term=NCT01109264&rank=1>.

7 SUPPLEMENTAL QUESTIONS

No supplemental questions were addressed in this review.

8 ABOUT THIS DOCUMENT

This Clinical Guidance Report was prepared by the pCODR Leukemia Clinical Guidance Panel and supported by the pCODR Methods Team. This document is intended to advise the pCODR Expert Review Committee (pERC) regarding the clinical evidence available on Bendamustine (Treanda) for CLL. Issues regarding resource implications are beyond the scope of this report and are addressed by the relevant pCODR Economic Guidance Report. Details of the pCODR review process can be found on the pCODR website (www.pcodr.ca).

pCODR considers it essential that pERC recommendations be based on information that can be publicly disclosed. Information included in the Clinical Guidance Report was handled in accordance with the *pCODR Disclosure of Information Guidelines*. The manufacturer, as the primary data owner, did not agree to the disclosure of some clinical information, which was provided to pERC for their deliberations, and this information has been redacted in this publicly posted Guidance Report.

This Final Clinical Guidance Report is publicly posted at the same time that a pERC Final Recommendation is issued. The Final Clinical Guidance Report supersedes the Initial Clinical Guidance Report. Note that no revisions were made in between posting of the Initial and Final Guidance Reports.

The Leukemia Clinical Guidance Panel is comprised of three clinical oncologists. The panel members were selected by the pCODR secretariat, as outlined in the pCODR Nomination/Application Information Package, which is available on the pCODR website (www.pcodr.ca). Final selection of the Clinical Guidance Panels was made by the pERC Chair in consultation with the pCODR Executive Director. The Panel and the pCODR Methods Team are editorially independent of the provincial and territorial Ministries of Health and the provincial cancer agencies.

APPENDIX A: LITERATURE SEARCH STRATEGY

1. Literature Search via OVID Platform.

Ovid MEDLINE (R), Ovid MEDLINE (R) In-Process & Other Non-Indexed Citations, and Ovid MEDLINE (R) Daily Update.

1. (bendamustine: or treanda: or ribomustin: or sdx-105: or hsd7763:).ti,ab,rn,nm,sh,hw,ot.
2. 3543-75-7.rn,nm.
3. 16506-27-7.rn,nm.
4. Or/1-3
5. Exp leukemia, lymphocytic, Chronic, B-Cell/
6. CLL: .ti,ab,sh,hw,ot.
7. Chronic lymph: leuke?mia: .ti,ab,sh,hw,ot.
8. or/5-7
9. 4 and 8

Ovid EMBASE

1. exp *bendamustine/
2. (bendamustine: or treanda: or ribomustin: or sdx-105: or hsd7763:).ti,ab.
3. 1 or 2
4. Exp *chronic lymphatic leukemia/
5. Chronic lymph: leuk?emia: .ti,ab.
6. CLL: .ti,ab.
7. Or/4-6
8. 3 and 7

2. Literature Search via PubMed

PubMed

1. bendamustine* or treanda* or ribomustin* or sdx-105* or hsd7763*
2. publisher[sb]
3. 1 and 2

3. Literature Search via Cochrane Central Register of Controlled Trials (CENTRAL)

Issue 8, 2012

29 results for: bendamustine* or treanda* or ribomustin* or sdx-105* or hsd7763* in Cochrane Central Register of Controlled Trials.

4. Grey Literature Searches

Clinical Trial Registries:

U.S. NIH ClinicalTrials.gov
www.clinicaltrials.gov

Ontario Institute for Cancer. Ontario Cancer trials
www.ontariocancertrials.ca

Search terms: bendamustine, treanda, ribomustin, sdx-105, hsd7763

Select International Agencies:

Food and Drug Administration (FDA):
www.fda.gov

European Medicines Agency (EMA):
www.ema.europa.eu

Search terms: bendamustine, treanda, ribomustin, sdx-105, hsdb 7763

Conference Abstracts:

American Society of Clinical Oncology (ASCO)
via the Journal of Clinical Oncology search portal: <http://jco.ascopubs.org/search>

American Society of Hematology (ASH)
via Blood (Journal of the American Society of Hematology) search portal:
<http://bloodjournal.hematologylibrary.org/search>

Search terms: bendamustine, treanda, ribomustin, sdx-105, hsdb 7763

REFERENCES

1. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. *J Clin Oncol*. 2009 Sep 10;27(26):4378-84.
2. Knauf WU, Lissichkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. *Br J Haematol*. 2012 Aug 4:[Epub] DOI: 10.1111/bjh.12000. Available from: <http://onlinelibrary.wiley.com/store/10.1111/bjh./asset/bjh.pdf?v=1&t=h6z2jkbfs&s=e06d17b805dfb4b81b931d8d12c173caba827511>.
3. Knauf WU, Lissichkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, et al. Bendamustine induces higher remission rates, prolongs progression free survival as well as time to next treatment, and improves overall survival for patients in complete remission without compromising quality of life when compared to chlorambucil in first line treatment of chronic lymphocytic leukemia. *Blood*. 2010 19 Nov;116(21):Abstract 2449.
4. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, et al. Bendamustine in the treatment of chronic lymphocytic Leukemia -consistent superiority over chlorambucil in elderly patients and across clinically defined risk groups. *Blood*. 2009 20 Nov;114(22):Abstract 2367.
5. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, et al. Bendamustine versus chlorambucil as first-line treatment in B cell chronic lymphocytic leukemia: an updated analysis from an international phase III study [abstract]. *Blood (ASH Annual Meeting Abstracts)*. 2008;112:Abstract 2091.
6. Knauf WU, Lissichkov T, Aldaoud A, Herbrecht R, Liberati AM, Loscertales J, et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international phase III study. *Blood*. 2007;110(11):609a, Abstract 2043. Available from: <http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/025/CN-00635025/frame.html>.
7. Knauf WU, Lissichkov T, Herbrecht R, Loscertales J, Aldaoud A, Merkle K. Bendamustine versus chlorambucil in treatment-naive B-CLL patients. *Blood [serial on the Internet]*. 2004; (11 (Pt 2)): Available from: <http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/925/CN-00546925/frame.html>.
8. Knauf WU, Lissichkov T, Raoul H, Aldaoud A, Merkle KH. Bendamustine versus chlorambucil in treatment-naive B-CLL patients - results of a safety analysis. *Blood [serial on the Internet]*. 2003; (11 (Pt 2)): Available from: <http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/658/CN-00484658/frame.html>.
9. Knauf U, Lissichkov T, Aldoud A, Herbrecht R, Liberati A, Loscertales J, et al. Bendamustine versus chlorambucil in treatment-naive patients with chronic lymphocytic leukemia: Updated results of an international phase III study. *Haematologica*. 2009 June;94:141, Abstract 0355.
10. Howlander N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. (eds). *SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 populations)*. Bethesda, MD: National Cancer Institute; 2012 Apr 30 [cited 2012 Jul 18]. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/.

11. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *Lancet*. 2010 Oct 2;376(9747):1164-74.
12. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. *N Engl J Med*. 2000 Dec 14;343(24):1750-7.
13. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, et al. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. *J Clin Oncol*. 2001 Aug 15;19(16):3611-21.
14. Chen CI, Bergsagel PL, Paul H, Xu W, Lau A, Dave N, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. *J Clin Oncol*. 2011 Mar 20;29(9):1175-81.
15. Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. *Blood*. 2011 Jun 16;117(24):6450-8.
16. Van der Jagt R, Laneuville P, MacDonald D, Stewart D, Christofides A, Sehn LH. A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. *Current Oncology*. 2012;19(3):160-8.
17. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. *Clin Cancer Res*. 2008;14(1):309-17.
18. pan-Canadian Oncology Drug Review Manufacturer Submission: Treanda (bendamustine hydrochloride): Lyophilized powder for injection, for intravenous infusion: 25 mg and 100 mg. Company: Lundbeck Canada Inc. Montreal (QC): Lundbeck Canada Inc.; 2012 Apr 24.
19. Treanda (bendamustine hydrochloride) lyophilized powder for injection: 25 mg/vial and 100 mg/vial [product monograph]. Montreal (QC): Lundbeck Canada Inc.; 2012 Aug 21.
20. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Medical review [Internet]. In: Treanda (bendamustine hydrochloride) injection. Company: Cephalon, Inc. Application no.: 022249. Approval date 2008 Mar 20. Rockville (MD): The Center; 2009 [cited 2012 May 31]. (FDA drug approval package). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/treanda_022249_TOC.cfm.
21. Montserrat E, Campo E. Small lymphocytic lymphoma/chronic lymphocytic leukemia. In: Canellos GP, Lister TA, Young B, editors. *The lymphomas*. 2nd ed. Philadelphia, PA: Saunders; 2006. p. 406-11.
22. Muller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. *WHO classification of tumours of haematopoietic and lymphoid tissue*. 4th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2008.
23. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. *Blood*. 1975 Aug;46(2):219-34.
24. Binet JL, Lepoprier M, Dighiero G, Charron D, D'Athis P, Vaugier G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. *Cancer*. 1977 Aug;40(2):855-64.

25. Bosch F, Montserrat E. Prognostic indicators in chronic lymphocytic leukemia. In: Faguet GB, editor. *Chronic lymphocytic leukemia : molecular genetics, biology, diagnosis, and management*. Humana Press: Totowa, N.J.; 2004. p. 201-15.
26. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. *Blood*. 1999 Sep 15;94(6):1840-7.
27. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. *Blood*. 1999 Sep 15;94(6):1848-54.
28. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. *N Engl J Med*. 2003 May 1;348(18):1764-75.
29. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrikson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. *Blood*. 2003 Jun 15;101(12):4944-51.
30. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. *Blood*. 2002 Feb 1;99(3):1023-9.
31. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. *Leukemia*. 2007 Sep;21(9):1885-91.
32. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. *N Engl J Med*. 1998 May 21;338(21):1506-14.
33. French Cooperative Group on Chronic Lymphocytic Leukemia. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. *Blood*. 1990 Apr 1;75(7):1414-21.
34. French Cooperative Group on Chronic Lymphocytic Leukemia. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia. *Blood*. 1990 Apr 1;75(7):1422-5.
35. Jaksic B, Brugiatelli M, Krc I, Losonczy H, Holowiecki J, Planinc-Peraica A, et al. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. *Cancer*. 1997 Jun 1;79(11):2107-14.
36. Medgenberg D, Balleisen L, Heit W, Knauf W, Weib J, Freier W, et al. Bendamustine vs. fludarabine as second-line treatment in chronic lymphocytic Leukemia. *European Journal of Cancer, Supplement*. 2009 September;7(2-3):563.
37. Koppler H, Fuss H, Hurtz HJ, Knigge O, Losem C, Reschke D, et al. Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): Results of a multicentre phase II study of the German CLL Study Group (GCLLSG). *Br J Haematol*. 2012 July;158(2):238-41.
38. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a

- multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. *J Clin Oncol*. 2011 Sep 10;29(26):3559-66.
39. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. *J Cancer Res Clin Oncol*. 2002 Nov;128(11):603-9.
 40. Weide R, Heymanns J, Gores A, Koppler H. Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas. *Leuk Lymphoma*. 2002 Feb;43(2):327-31.
 41. Kath R, Blumenstengel K, Fricke HJ, Hoffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. *J Cancer Res Clin Oncol*. 2001 Jan;127(1):48-54.
 42. Bendamustine (Treanda) for CLL and NHL. [Erratum appears in *Med Lett Drugs Ther*. 2008 Dec 1;50(1300):96]. *Med Lett Drugs Ther*. 2008 Nov 17;50(1299):91-2.
 43. Bendamustine (Treanda) for CLL and NHL (Medical Letters on Drugs Therapeutics (2008) 50, (91)). *Medical Letter on Drugs and Therapeutics*. 2008 01 Dec;50(1300):96.
 44. Montillo M. Is bendamustine an ideal partner for rituximab in the management of relapsed chronic lymphocytic leukemia? Results of a multicenter Phase II trial. *Expert Rev Hematol*. 2012 Feb;5(1):43-6.
 45. Rummel MJ. Optimal dosing and scheduling of bendamustine. *Clinical Advances in Hematology and Oncology*. 2009 October;7(10):10-3.
 46. Weide R, Pandorf A, Heymanns J, Koppler H. Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. *Leuk Lymphoma*. 2004 Dec;45(12):2445-9.
 47. Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. *Haematologica*. 2005 Oct;90(10):1357-64.
 48. Koppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. *Leuk Lymphoma*. 2004 May;45(5):911-3.
 49. Lissitchkov T, Arnaudov G, Peytchev D, Merkle K. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. *J Cancer Res Clin Oncol*. 2006 Feb;132(2):99-104.
 50. Ujjani CS, Karim SM, Goswami T, Crawford J, Gehan EA, Kessler C, et al. Bendamustine and lenalidomide in relapsed/refractory CLL. *Clinical Lymphoma, Myeloma and Leukemia*. 2011 October;11:S245.
 51. Cortelezzi A, Liberati AM, Gritti G, Cuneo A, Reda G, Laurenti L, et al. Combination of bendamustine and ofatumumab (bendofa) in patients with relapsed/refractory chronic lymphocytic leukemia: A preliminary report. *Clinical Lymphoma, Myeloma and Leukemia*. 2011 October;11:S248-S9.
 52. De Miguel MD, Golbano N, Diaz Morfa M, Lopez-San Roman I, Morales D, Arbeteta J, et al. Clinical results of bendamustine plus rituximab for indolent NHL and CLL. Experience of only one institution. *Haematologica*. 2010 June;95:694.
 53. Flinn IW, Schreeder MT, Coutre SE, Leonard J, Wagner-Johnston ND, De Vos S, et al. A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110, in combination with

anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies. *J Clin Oncol*. 2011 20 May;29(15 Suppl):Abstract 3064.

54. Brown JR, Jahn TM, Furman RR, Leonard JP, Spurgeon SE, Byrd JC, et al. Patterns of nodal response and lymphocytosis in patients with previously treated CLL receiving the selective phosphatidylinositol 3-kinase-delta (PI3K) inhibitor, cal-101 (GS-1101) alone or in combination with rituximab (R) or bendamustine (B). *Clinical Lymphoma, Myeloma and Leukemia*. 2011 October;11:S272-S3.
55. Hallek M, Bergmann M, Goede V, Fingerle-Rowson G, Schweighofer C, Schmitt B, et al. [Current concepts in chronic lymphocytic leukemia. Better chances for young patients]. *MMW Fortschr Med*. 2003 Jul 10;145(27-28):46-9.
56. Dzięczenia J, Wrobel T, Mazur G, Woolwiec D, Butrym A, Stefanko E, et al. Efficacy of bendamustine +/- rituximab in the treatment of chronic lymphocytic leukemia - single center experience and literature review. [Polish]. *Acta Haematologica Polonica*. 2011;42(2):251-5.
57. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Summary review [Internet]. In: Treanda (bendamustine hydrochloride) injection. Company: Cephalon, Inc. Application no.: 022249. Approval date 2008 Mar 20. Rockville (MD): The Center; 2009 [cited 2012 May 31]. (FDA drug approval package). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/treanda_022249_TOC.cfm.
58. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Statistical review [Internet]. In: Treanda (bendamustine hydrochloride) injection. Company: Cephalon, Inc. Application no.: 022249. Approval date 2008 Mar 20. Rockville (MD): The Center; 2009 [cited 2012 May 31]. (FDA drug approval package). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/treanda_022249_TOC.cfm.
59. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 Feb 29-. Identifier NCT01423032, Bendamustine versus fludarabine in chronic lymphocytic leukemia (CLL); 2011 Aug 19 [Last updated 2011 Aug 24; cited 2012 May 31]. Available from: <http://clinicaltrials.gov/ct2/show/NCT01423032?term=01423032&rank=1>.
60. Lundbeck Canada Inc. response to checkpoint meeting questions [internal report]. Montreal (QC): Lundbeck Canada Inc.
61. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 Feb 29-. Identifier NCT00769522, FCR or BR in patients with previously untreated B-cell chronic lymphocytic leukemia (CLL10); 2008 Oct 8 [Last updated 2012 Mar 14; cited 2012 Sep 6]. Available from: <http://clinicaltrials.gov/ct2/show/NCT00769522?term=nct00769522&rank=1>.
62. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 Feb 29-. Identifier NCT01657955, Bendamustine hydrochloride injection for previously untreated chronic lymphocytic leukemia (CLL); 2012 Aug 2 [Last updated 2012 Aug 3; cited 2012 Sep 10]. Available from: <http://clinicaltrials.gov/ct2/show/NCT01657955?term=NCT01657955&rank=1>.
63. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 Feb 29-. Identifier NCT01109264, Bendamustine hydrochloride injection for initial treatment of chronic lymphocytic leukemia; 2010 Apr 19 [Last updated 2012 May 18; cited 2012 Sep 10]. Available from: <http://clinicaltrials.gov/ct2/show/NCT01109264?term=NCT01109264&rank=1>.